title: Telithromycin in the treatment of pneumococcal community-acquired respiratory tract infections: a review.
abstract: OBJECTIVE
  A pooled analysis of 14 Phase III studies was performed to establish the clinical and bacteriologic efficacy of telithromycin 800 mg once daily in the treatment of pneumococcal community-acquired respiratory tract infections (RTIs).
  
  
  METHODS
  Data were examined from 5534 adult/adolescent patients with community-acquired pneumonia (CAP), acute exacerbations of chronic bronchitis (AECB), or acute bacterial sinusitis, who had received telithromycin for 5-10 days or a comparator antibacterial.
  
  
  RESULTS
  Streptococcus pneumoniae was identified in 704/2060 (34.2%) bacteriologically evaluable patients. The respective per-protocol clinical cure rates for telithromycin and comparators were 94.3% and 90.0% (CAP); 81.5% and 78.9% (AECB); 90.1% and 87.5% (acute sinusitis); 92.7% and 87.6% (all indications). Clinical cure rates were 28/34 (82.4%) and 5/7, respectively, for penicillin-resistant infections, and 44/52 (84.6%) and 11/14, respectively, for erythromycin-resistant infections. Of 82 patients with pneumococcal bacteremia, 74 (90.2%) were clinically cured after telithromycin treatment, including 5/7 and 8/10 with penicillin- or erythromycin-resistant strains, respectively. Adverse events considered possibly related to study medication were reported by 1071/4045 (26.5%) telithromycin and 505/1715 (29.4%) comparator recipients. These events were generally of mild/moderate severity, and mainly gastrointestinal in nature.
  
  
  CONCLUSIONS
  As S. pneumoniae is the leading bacterial cause of community-acquired RTIs, and antibacterial resistance is increasing among this species, these findings support the use of telithromycin as first-line therapy in this setting.
authors.affiliation: Spartanburg Pharmaceutical Research, 126 Dillon Street, Spartanburg, SC 29307, USA.
authors.forename: Charles M
authors.initials: CM
authors.lastname: Fogarty
authors.forename: Patricia
authors.initials: P
authors.lastname: Buchanan
authors.forename: Michel
authors.initials: M
authors.lastname: Aubier
authors.forename: Malik
authors.initials: M
authors.lastname: Baz
authors.forename: Dirkie
authors.initials: D
authors.lastname: van Rensburg
authors.forename: Manickam
authors.initials: M
authors.lastname: Rangaraju
authors.forename: Roomi
authors.initials: R
authors.lastname: Nusrat
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D017714:Community-Acquired Infections / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D048628:Ketolides / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D011008:Pneumococcal Infections / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D012141:Respiratory Tract Infections / Q000188:drug therapy*; D013296:Streptococcus pneumoniae / Q000187:drug effects / Q000302:isolation & purification; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D048628:Ketolides; C106791:telithromycin